Iron Overload Management in Anemic Patients

Diagnosis and Assessment

The American Society of Hematology recommends calculating Transferrin saturation (TSAT) to assess iron overload, where TSAT >20% with ferritin >100 ng/mL indicates functional iron deficiency, not absolute iron deficiency requiring supplementation 1, 2
A TSAT of 41% and ferritin of 508 ng/mL indicate adequate iron stores, and iron supplementation should not be given despite anemia 2, 1
Low TIBC (178) suggests chronic disease/inflammation or iron overload, not iron deficiency 1

The American Journal of Hematology suggests investigating the underlying cause of anemia and iron overload before initiating therapy, including transfusion history, myelodysplastic syndrome, chronic kidney disease, and genetic iron disorders 3, 4, 5, 6
Iron chelation therapy with deferasirox is indicated for patients with ferritin ≥1,000 ng/mL, transfusion requirement ≥2 units/month for >1 year, or need to preserve organ function 5, 1
The American College of Cardiology recommends monitoring serum ferritin, complete blood count, liver and renal function, and TSAT at regular intervals to assess treatment response and potential toxicity 5, 1

For patients with ferroportin disease, phlebotomy is the primary treatment, but if anemia develops during phlebotomy, extending phlebotomy intervals and considering EPO therapy may be necessary 3, 4
For stem cell transplant candidates, iron chelation should be considered even at lower ferritin levels (>1,000 ng/mL) to reduce transplant-related mortality and hepatic complications 6, 5

The Annals of Oncology warns against giving oral or IV iron based solely on low hemoglobin when ferritin is elevated and TSAT is adequate 2, 1
The American Journal of Hematology advises against starting chelation prematurely (ferritin <1,000 ng/mL) unless specific indications exist, and against continuing chelation if ferritin falls below 500 ng/mL 5, 1